Search
Experience the words and artwork of three patients who found hope and healing through MSK art programs.
Rather than promoting genetic chaos, loss of p53 leads to an orderly progression of genetic changes that no one saw coming.
Recent advances in technology allow Memorial Sloan Kettering Cancer Center pathologists to perform swift and accurate molecular analyses of tumor cells in patients with colorectal cancer. By determining the gene mutations of individual tumors, doctors are able to prescribe treatments that are most likely to be effective for patients, while avoiding drugs that will provide no benefit and may cause serious side effects.
Learn about the work of Nai-Kong Cheung and other MSK scientists who have learned more about how to deliver stronger treatment with less toxicity.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.
Crain’s New York Business announced that MSK’s Mike Czumak, Vice President, Chief Information Security Officer, is included on its 2021 Notable Veterans Executive List.
A former teacher and volunteer firefighter benefits from less-intense treatment for early stage-esophageal cancer.
Each year since 2007, Memorial Sloan Kettering's postdoctoral researchers have had the opportunity to showcase their research accomplishments at the annual Postdoctoral Research Symposium.